focus -WSS

focus

author：fashion 2025-09-30 04:09:38 Page View：789

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Stephen Quake on the Chan Zuckerberg quest to conquer disease
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

FREDERICJ.BROWN/AFPviaGettyImagesWhentemperaturessoar,sodoheartattacks.Now,alabexperimentexplainsjus

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Pharma companies must ensure equitable access to obesity drugs

TheobesitydrugWegovyisseenatapharmacyinChicago.ScottOlson/GettyImagesWeightlosstreatmentshavethepote

focus

knowledge

explore

Pharma companies must ensure equitable access to obesity drugs